Vedolizumab for De Novo Ulcerative Colitis After Kidney Transplantation in a Patient With IgA Nephropathy: A Case Report

Source: PubMed Central Open Access, NCBI / U.S. National Library of Medicine

De novo inflammatory bowel disease (IBD) is a rare but important cause of diarrhea after kidney transplantation (KT). Experience with newer biological agents in the management of IBD among KT recipients remains limited. Vedolizumab is an47 integrin antagonist that selectively blocks a subset of gastrointestinal‐homing lymphocytes, which limits systemic immunosuppression and, compared to other biologic agents or novel molecules, may reduce the risk of overimmunosuppression in the setting of KT. We report the case of a KT recipient with IgA nephropathy as the underlying cause of chronic kidney disease, who developed de novo ulcerative colitis after KT and was successfully treated with vedolizumab without experiencing adverse reactions during the 29 months of follow‐up.